VOLUME 10 (2019)
View Archive »
About The Cover
The cover for issue 6 of Oncotarget features Figure 5, "AKT-specific inhibitor MK2206 decreases cell viability, spheroid formation, and migration of SETD2 deficient ccRCC-derived cells," by Terzo, et al.
|
|
Table of Contents
News
|
| CDK4/6 inhibition alone and in combination for nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.26545
|
| 618-619 |
Editorial
|
| DNA polymerases as chemotherapy targets: promise and challenges |
|
https://doi.org/10.18632/oncotarget.26572
|
| 620-621 |
|
| Role of transcriptionregulating kinase CDK8 in colon cancer metastasis |
|
https://doi.org/10.18632/oncotarget.26593
|
| 622-623 |
|
| Concurrent chemotherapy in oropharyngeal cancer: Cisplatin wins |
|
https://doi.org/10.18632/oncotarget.26594
|
| 624-625 |
|
| The dawn of a new era in treating TPLL |
|
https://doi.org/10.18632/oncotarget.26595
|
| 626-628 |
|
| AEG1 targeting for inhibiting inflammation: potential antiHCC strategy |
|
https://doi.org/10.18632/oncotarget.26602
|
| 629-630 |
|
| Modeling the prevalent germline TP53 R337H mutation in mouse |
|
https://doi.org/10.18632/oncotarget.26603
|
| 631-632 |
Research Papers
|
| Carbon ion irradiation enhances the antitumor efficacy of dual immune checkpoint blockade therapy both for local and distant sites in murine osteosarcoma |
|
https://doi.org/10.18632/oncotarget.26551
|
| 633-646 |
|
| SETD2 loss sensitizes cells to PI3Kβ and AKT inhibition |
|
https://doi.org/10.18632/oncotarget.26567
|
| 647-659 |
|
| Preoperative MRIradiomics features improve prediction of survival in glioblastoma patients over MGMT methylation status alone |
|
https://doi.org/10.18632/oncotarget.26578
|
| 660-672 |
|
| Downregulation of miR1945p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression |
|
https://doi.org/10.18632/oncotarget.26586
|
| 673-683 |
Corrections
|
| Correction: Upregulation of p16 by miR8773p inhibits proliferation of bladder cancer |
|
https://doi.org/10.18632/oncotarget.26624
|
| 684-684 |
|
| Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer |
|
https://doi.org/10.18632/oncotarget.26625
|
| 685-685 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC